期刊文献+

反相高效液相色谱法测定人血浆酮康唑与伏立康唑 被引量:4

下载PDF
导出
摘要 目的建立同时检测人血浆酮康唑和伏立康唑的高效液相色谱法。方法血浆经乙酸乙酯-正己烷萃取,以AgilentTC-C18为色谱柱;流动相为乙腈-0.1%三氟乙酸-水体系,流速为0.9mL·min-1;检测波长294(0~6.5min),256nm(6.5~9min)。结果酮康唑浓度在0.25~16.00mg·mL-1范围内线性关系良好(r=0.9999),定量下限为0.25mg·mL-1,高、中、低3个浓度日内RSD分别为5.35%,3.65%和2.70%,日间RSD分别为5.81%,3.50%和3.08%。伏立康唑在0.025~1.600mg·mL-1范围内线性关系良好(r=0.9999),定量下限为0.025mg·mL-1,高、中、低3个浓度的日内RSD分别为5.09%,3.70%和2.89%,日间RSD分别为5.36%,3.86%和2.94%。结论该方法简便、快速,准确可靠,适用于人血浆酮康唑和伏立康唑的测定及其药动学研究。
出处 《医药导报》 CAS 2009年第5期590-592,共3页 Herald of Medicine
  • 相关文献

参考文献7

二级参考文献35

  • 1姚斌,金永生,潘亚菊.伏立康唑拆分方法的改进[J].第二军医大学学报,2004,25(6):691-691. 被引量:4
  • 2王晓玲.HPLC法测定抗真菌药伏立康唑的有关物质[J].西南民族大学学报(自然科学版),2004,30(5):595-597. 被引量:3
  • 3黄圣凯,韩可勤.生物等效性评价的几种统计方法[J].中国临床药理学杂志,1993,9(1):43-46. 被引量:125
  • 4南志成.高效液相色谱法测定人血浆中伏立康唑浓度[J].中国医院药学杂志,2006,26(7):836-839. 被引量:16
  • 5戴富宝 李玲.高效液相色谱法测定酮康唑及其制的含量[J].药物分析杂志,1990,10(4):232-232.
  • 6[1]Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J].N Engl J Med,2002,347(6):408-415.
  • 7[2]Perfect JR,Marr KA,Walsh TJ,et al.Voriconazole treatment for less-common,emerging,or refractory fungal infections[J].Clin Infect Dis,2003,36(9):1122-1131.
  • 8[3]Pfaller MA,Diekema DJ,Rex JH,et al.Correlation of MIC with outcome for Candida species tested against voriconazole:analysis and proposal for interpretive breakpoints[J].J Clin Microbiol,2006,44(3):819-826.
  • 9[4]Theuretzbacher U,Ihle F,Derendorf H.Pharmacokinetic/pharmacodynamic profile of voriconazole[J].Clin Pharmacokinet,2006,45(7):649-663.
  • 10[5]R Hyland,BC Jones,DA Smith.Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole[J].Drug Metab Dispos,2003,31(5):540-547.

共引文献48

同被引文献22

  • 1曹卫菊,盛国荣.分光光度法测定复方水杨酸涂膜剂中水杨酸和酮康唑含量[J].抗感染药学,2004,1(1):33-34. 被引量:2
  • 2史卉妍,彭亮,谭志荣,康桢,何鑫,罗丽芳,吴卫华,阳国平,欧阳冬生.高效液相色谱法测定人血浆中伏立康唑浓度[J].中南药学,2007,5(4):305-308. 被引量:29
  • 3陈祝康,王林波,杨美成,等.电位滴定法测定酮康唑含量能力验证的结果分析[J].中国医药上业杂志,2009,40(10):766-769.
  • 4Kazuaki M, Kazuro I, kazu ko A, et al. Correlation between vori- conazole through plasma concentration and hepatotoxicity in pa- tients with different CYP2CI9 genotypes [ J]. Int J Antimicrob Agents,2009,34( 1 ) :91-94.
  • 5Potoskib A, Brown J. The safety of voriconazole [ J ]. Clin Intact Dis, 2002,35 ( 10 ) : 1273-1275.
  • 6LEVEQUE D, NIVOIX Y, JEHL F, et al. Clinical phar- macokinetics of voriconazole [ J ]. Int J Antimicrob Agents, 2006,27 (4) :274-284.
  • 7THEURETZBACHER U, IHLE F, DERENDORF H, et al. Phamacokinetic/pharmacodynamic profile of voriconazole [J]. Clin Pharmacokinet, 2006,45 ( 7 ) :649-663.
  • 8ARAUJO B V,CONRADO D J, PALMA E C, et al. Valida- tion of rapid and simple LC-MS/MS method for determination of voriconazole in rat plasma [ J ]. J Phallnaceut Biomed Anal ,2007,4 (44) :985-990.
  • 9LEI Z, RANDOLPH DG, NANCY C, et al. Determination of voriconazole in aqueous humor by liquid chromatography- electrospray ionization-mass spectrometry [ J ]. J Chromat B,2002,776(2) :213-220.
  • 10CHHUN S, REY E, TRAN A, et al. Simultaneous quanti- fication of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection[J].J Chromat B,2007,852(1-2) :223-228.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部